Power-speed-endurance Profile (Cycling/Rowing) : Optimize Performance of the French Athletes at the Paris Olympics 2024 (THPCA2024)

Description and Determinants of the Power-speed-endurance Profile (PVE) in Cycling and Rowing to Optimize the Performance of the French Athletes at the Paris Olympics 2024

As part of the preparation at the Paris 2024 Olympic Games, the French rowing and cycling federations and a consortium of researchers met to reach an ultimate goal: to increase the number of medals in these two disciplines for Paris 2024 Olympics.

Study Overview

• Status: Recruiting
• Conditions: Healthy Volunteers; Performance
• Intervention / Treatment: Other: Hypoxia

Detailed Description

The objective of this study is to evaluate the maximum capacity of power production of athletes by describing their power-endurance profile and the physiological factors underlying this maximum power generation capacity. These assessments will guide coaches and athletes for:

1. the best use of athletes' physical abilities (for race strategy, cycling gear ratio or rowing levers)
2. adaptation of training program to improve the maximum capacity of power production of the athletes, in order to increase the number of medals at the Paris Olympics 2024.

• Study Type: Interventional
• Enrollment (Estimated): 60
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Léonard FEASSON, PhD; Phone Number: +33 (0)477120383; Email: leonard.feasson@chu-st-etienne.fr
• Study Contact Backup: Name: Laurent MESSONNIER, PhD; Phone Number: +33 04 79 75 81 85; Email: laurent.messonnier@univ-smb.fr

Study Locations

• France
  • Le Bourget-du-Lac, France, 73370
    • Recruiting
    • CEPART
    • Sub-Investigator: Fabrice DESCOMBE, MD
    • Principal Investigator: Etienne DALMAIS, MD
  • Nantes, France, 44000
    • Not yet recruiting
    • CHU Nantes
    • Principal Investigator: Raphaël GROSS, MD-PhD
  • Saint-Étienne, France, 42055
    • Recruiting
    • CHU Saint-Etienne
    • Principal Investigator: Léonard FEASSON, MD PhD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• experienced, well-trained (national to international level) rowers and cyclists
• written consent

Exclusion Criteria:

• taking medications interfering with measured parameters
• contraindication to competitive sport practice
• currently participating in an other structured exercise program
• muscular, bone or joint injuries
• neurologic disease
• pregnant

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Track cyclists and rowers (males and females); All female and male rowing and track cycling athletes at the national or international national or international level, registered in a selection process and likely to represent France at the likely to represent France at the 2024 Olympics will be asked to take part to take part in this study.

Other: Hypoxia; Subjects will be subjected to mild hypoxia simulating an altitude of 1750 m (normobaric hypoxia). Hypoxia decreases oxygen supply to tissue and limit exercise capacity. For this, the subjects will inhale a gas mixture depleted in oxygen (enriched in nitrogen). The barometric pressure at 1500 m being 621 mmHg, PIO2 at this altitude (PIO2 = (621 - 47) x 21%) is 120.5 mmHg. For sea level altitude where the barometric pressure is 760 mmHg, the hypoxic gas mixture should contain (x = 120.5 / (760 - 47)) 16.8% O2. Thus, by inhaling a gas mixture that is oxygen-depleted from 21 to 16.8%, subjects (will simulate the altitude of 1750 and) will experience the equivalent of a 20% reduction in oxygen supply.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Maximum force produced at zero speed in a fatigue-free condition	F0i measurement	Month : 3
Speed in a fatigue-free condition	V0i measurement	Month : 3
Maximum force produced at zero speed at the end of the 3 min.	F0e measurement	Month : 3
Speed up produced at the end of the 3 min.	V0e measurement	Month : 3

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Maximal oxygen uptake (VO2max)	Cardiac stress test	At inclusion
Maximal Ventilation (VEmax)	Cardiac stress test	At inclusion
Cardiac output (QCmax)	Cardiac stress test	At inclusion
Maximal cardiac frequency (fcmax)	Cardiac stress test	At inclusion
Fibre type determination	Muscle biopsy of the vastus lateralis	Month : 2
Microvasculature analysis	Muscle biopsy of the vastus lateralis	Month : 2
Muscle enzyme activity (Phosphofructokinase (PFK), lactate dehydrogenase (LDH), citrate synthase (CS) et cyclo-oxygenase (COx))	Muscle biopsy of the vastus lateralis	Month : 2
Maximal voluntary force (N)	Comparison before and after exercise	Month : 9
Rate of force development	Comparison of force development	Month : 9
Evoked forces (N)	Ratio of evoked force at low and high frequencies	Month : 9

Collaborators and Investigators

• Sponsor: Centre Hospitalier Universitaire de Saint Etienne
• Investigators: Principal Investigator: Léonard FEASSON, PhD, CHU Saint-Etienne; Study Director: Laurent MESSONNIER, PhD, Université Savoie Mont Blanc, CHAMBERY

Study record dates

Study Major Dates

• Study Start (Actual): November 29, 2021
• Primary Completion (Estimated): August 1, 2024
• Study Completion (Estimated): August 1, 2024

Study Registration Dates

• First Submitted: February 2, 2022
• First Submitted That Met QC Criteria: April 5, 2022
• First Posted (Actual): April 6, 2022

Study Record Updates

• Last Update Posted (Actual): April 16, 2024
• Last Update Submitted That Met QC Criteria: April 15, 2024
• Last Verified: April 1, 2024

More Information

Terms related to this study

• Keywords: Fatigue; Biomechanics; Muscle; Energetics; Track cyclists and rowers
• Other Study ID Numbers: 21CH145; 2021-A02341-40 (Other Identifier: ANSM)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No